The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLII.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

DAH can be reversed by idarucizumab therapy

Publications

Shiroshita A, Nakashima K, Tanaka Y, Tateishi A, Nemoto M, Aoshima M

Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report.

Journal of thrombosis and thrombolysis 2018 Aug;46;271-273 — 2018 Aug — 271-273

Chen BC, Sheth NR, Dadzie KA, Smith SW, Nelson LS, Hoffman RS, Winchester JF

Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2013 Sep;62;591-4 — 2013 Sep — 591-4

Yokoi K, Isoda K, Kimura T, Adachi T

Diffuse alveolar hemorrhage associated with dabigatran.

Internal medicine (Tokyo, Japan) 2012;51;2667-8 — 2012 — 2667-8

Husari A, Beydoun A, Sheik Ammar A, Maakaron JE, Taher A

The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.

Journal of thrombosis and thrombolysis 2013 Jan;35;81-2 — 2013 Jan — 81-2